Aeroflow Sleep, a national durable medical equipment (DME) provider specializing in CPAP supplies, announced the results of a proprietary survey of 887 parents which revealed a hidden health crisis happening due to parental sleep deprivation, with more than a quarter of respondents showcasing signs of undiagnosed sleep apnea. Parents are […]
Industry News
AAST Takes Action to Support Sleep Technologists in CMS Reimbursement Proposal
The American Association of Sleep Technologists (AAST) has submitted formal comments to the Centers for Medicare & Medicaid Services (CMS) regarding proposed payment policies under the CY 2027 Medicare Physician Fee Schedule. Specifically, AAST provided feedback on the valuation of newly established unattended sleep testing CPT codes. This advocacy effort […]
AASM Announces Inclusion of New Unattended Sleep Testing CPT Codes in CMS Proposed Rule
New Current Procedural Terminology codes for unattended sleep testing have been included by the Centers for Medicare and Medicaid Services in the Medicare physician fee schedule proposed rule. The updated CPT code set, which the American Academy of Sleep Medicine helped develop and advance, is intended to better align coding […]
AADSM Reaches 2,500 Qualified Dentists Nationwide for OSA Oral Appliance Therapy
The American Academy of Dental Sleep Medicine (AADSM) announced that 2,500 dentists across the country have achieved AADSM Qualified Dentist status, strengthening patient access to oral appliance therapy (OAT) for obstructive sleep apnea (OSA). OAT offers a comfortable, clinically-proven treatment option for snoring and OSA. The therapy uses a custom-fit oral […]
HoneyNaps Develops Next-Generation Wireless PSG system Using Four Skin Patches
HoneyNaps, specializing in AI-powered sleep medical devices, has developed a next-generation wireless polysomnography system that combines patch-based skin sensors with artificial intelligence-driven analysis. Polysomnography (PSG) is the standard diagnostic test for sleep disorders such as sleep apnea. Conventional PSG, however, generally requires patients to spend a night at a hospital […]
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio System
Nyxoah SA announced that the first patient has been implanted in BREATHE, the Company’s U.S. post-approval study of the Genio® system. The procedure was performed by Rolando Molina, MD, otolaryngologist at South Florida ENT Associates. Edward Mezerhane, MD, FAASM, FACP, DABOM, CPI, sleep medicine physician at PharmaDev Clinical Research Institute […]
ProSomnus Prevails in Intellectual Property Lawsuit
ProSomnus Sleep Technologies (“ProSomnus”) has announced a significant victory in its intellectual property enforcement action, reinforcing the Company’s commitment to protecting the innovations, technologies, and proprietary assets that support advances in sleep medicine. The United States District Court for the Southern District of Florida adopted in full the Magistrate Judge’s Report […]
Haynes Boone Advises Cathay Capital and ReDream Brands on Strategic Sleep Health Transactions
Haynes Boone represented Cathay Capital and its portfolio company, cpap.com, in the acquisitions of Lofta, LLC from a subsidiary of Accendra Health, Inc, and The CPAPShop from a subsidiary of AdaptHealth Corp. with which a joint venture relationship was also structured, a debt refinancing with Twin Brook Capital Partners, and […]
CPAP Provider Competency Program Sets the Bar
The ASA has launched a brand new service to the CPAP industry – the CPAP Provider Competency Program. It offers CPAP providers an independent industry-wide education program for CPAP professionals who initiate and maintain patients on CPAP therapy. “This program is a way for CPAP providers to demonstrate their commitment […]
ORZEYFUL Approved in Japan for Narcolepsy Type 1 Treatment
Takeda announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat […]













